With SAJAZIR (icatibant), hereditary angioedema (HAE) treatment1 is within easy reach*
*SAJAZIR injection is a prefilled syringe for subcutaneous use.1 Patients should not inject SAJAZIR until they have been trained by a Cycle Vita product support nurse or their healthcare provider.
SAJAZIR is an FDA-approved injection indicated for the treatment of acute attacks of HAE in adults aged 18 years and older.1,2
So why choose SAJAZIR?1
SAJAZIR is an accessible, portable prefilled icatibant injection accompanied by broad product support, helping you have a seamless experience, from enrollment to treatment initiation and beyond.
Discuss with your healthcare provider if SAJAZIR is right for you.
Effective symptom reduction for HAE attacks,1 within easy reach*
SAJAZIR comes in the form of a convenient, portable, prefilled injection that you will be trained to self-administer subcutaneously as soon as you notice the signs of an HAE attack coming on.
SAJAZIR can be used to treat acute HAE attacks, including skin (cutaneous), stomach (abdominal), and throat (laryngeal).
In three clinical trials, icatibant has been shown in select patients to:1
Reduce symptoms by 50% in around 2 hours, with results ranging between 1.5–3 hours, even after multiple attacks (vs. almost 20 hours with placebo, in non-throat attacks) in one clinical trial with 43 patients
Achieve almost complete symptom relief in around 8 hours, with results ranging between 5.0 and 42.5 hours (vs. 36 hours with placebo) in one clinical trial with 43 patients
Treat 9 out of 10 attacks (93%) with a single dose in three clinical trials with 225 patients
It’s important to remember that HAE attacks of the throat (laryngeal attacks) can become life threatening—if you have a laryngeal attack, inject SAJAZIR and then go to the nearest hospital emergency room right away.
Start your SAJAZIR enrollment here
Download, complete and fax a PDF
- SAJAZIR™ (icatibant) Injection. Prescribing Information. Cycle Pharmaceuticals Limited.
- FDA. FDA-approved Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212446 (accessed October 2021).
Indication and Important Safety Information
SAJAZIR™ (Icatibant) injection is a medicine used to treat acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Laryngeal attacks can become life threatening. If you have an HAE attack of the throat (laryngeal attack), inject SAJAZIR and then go to the nearest hospital emergency room right away.
The most common side effects of SAJAZIR include:
- redness, bruising, swelling, warmth, burning, itching, irritation, hives, numbness, pressure, or pain at the injection site
- too much of an enzyme called transaminase in your blood
These are not all of the possible side effects of SAJAZIR. Tell your healthcare provider if you have any side effects.
Also tell your healthcare provider if you have any other medical conditions, are breastfeeding or plan to breastfeed, or if you are pregnant or planning to become pregnant. SAJAZIR has not been evaluated in pregnant or nursing women. You and your healthcare provider will decide if SAJAZIR is right for you.
If your symptoms continue or come back, you may repeat your SAJAZIR injection at least 6 hours apart. Do not use more than 3 doses of SAJAZIR in a 24-hour period.
Tiredness, drowsiness, and dizziness have been reported following the use of SAJAZIR. If this occurs, do not drive a car, use machinery, or do anything that needs you to be alert.
For more detailed information, please refer to the Full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS contact Cycle Pharmaceuticals at 1-800-836-4380, or the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch.